Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: A case report

Saved in:
Bibliographic Details
Published inExperimental hematology Vol. 41; no. 6; pp. 505 - 507
Main Authors Rahmé, Ramy, Benayoun, Emmanuel, Pautas, Cécile, Cordonnier, Catherine, Wagner-Ballon, Orianne, Maury, Sébastien
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 01.06.2013
Subjects
Adult
Advanced Basic Science
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Antigens, CD20 - biosynthesis
Antigens, CD20 - genetics
Antimetabolites, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Azacitidine - administration & dosage
Azacitidine - pharmacology
Combined Modality Therapy
DNA (Cytosine-5-)-Methyltransferase 1
DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors
Enzyme Inhibitors - pharmacology
Fatal Outcome
Female
Gene Expression Regulation, Leukemic - drug effects
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Transplantation
Histone Deacetylase Inhibitors - administration & dosage
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - surgery
Recurrence
Rituximab
Salvage Therapy
Transplantation, Homologous
Up-Regulation - drug effects
Valproic Acid - administration & dosage
Online AccessGet full text

Cover

More Information
ISSN:0301-472X
1873-2399
DOI:10.1016/j.exphem.2013.02.011